Cargando…

Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model

Sexual HIV-1 transmission by vaginal route is the most predominant mode of viral transmission, resulting in millions of new infections every year. In the absence of an effective vaccine, there is an urgent need to develop other alternative methods of pre-exposure prophylaxis (PrEP). Many novel drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neff, C. Preston, Ndolo, Thomas, Tandon, Apurva, Habu, Yuichiro, Akkina, Ramesh
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006206/ https://www.ncbi.nlm.nih.gov/pubmed/21203568 http://dx.doi.org/10.1371/journal.pone.0015257

Ejemplares similares

A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
por: Neff, C. Preston, et al.
Publicado: (2011)

Mucoadhesive Microspheres of Maraviroc and Tenofovir Designed for Pre-Exposure Prophylaxis of HIV-1: An in vitro Assessment of the Effect on Vaginal Lactic Acid Bacteria Microflora
por: Ekama, Sabdat O, et al.
Publicado: (2021)

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)
por: Herrera, Carolina, et al.
Publicado: (2021)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
por: Ananworanich, Jintanat, et al.
Publicado: (2015)

Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice
por: Denton, Paul W, et al.
Publicado: (2008)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
por: Treviño, Ana, et al.
Publicado: (2011)

Structural Basis of Mos1 Transposase Inhibition by the Anti-retroviral Drug Raltegravir
por: Wolkowicz, Urszula M., et al.
Publicado: (2014)

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
por: Ostrowski, Mario, et al.
Publicado: (2015)

Enzyme Responsive Vaginal Microbicide Gels Containing Maraviroc and Tenofovir Microspheres Designed for Acid Phosphatase-Triggered Release for Pre-Exposure Prophylaxis of HIV-1: A Comparative Analysis of a Bigel and Thermosensitive Gel
por: Ekama, Sabdat Ozichu, et al.
Publicado: (2021)

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
por: Jacobs, Tom G., et al.
Publicado: (2022)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

Humanized Rag1(−/−)γc(−/−) Mice Support Multilineage Hematopoiesis and Are Susceptible to HIV-1 Infection via Systemic and Vaginal Routes
por: Akkina, Ramesh, et al.
Publicado: (2011)

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
por: Lafeuillade, Alain, et al.
Publicado: (2014)

Uptake of retroviral pre-exposure prophylaxis and its associated factors among female sex workers, Northwest Ethiopia
por: Shibesh, Belayneh Fentahun, et al.
Publicado: (2023)

936 Tolerability, Adherence and Completion of New Occupational HIV Post-Exposure Prophylaxis Regimens (Tenofovir + Emtricitabine and Raltegravir)
por: Bock, Izona, et al.
Publicado: (2014)

886. Pregnancy Outcomes Following Raltegravir Exposure
por: Shamsuddin, Hala, et al.
Publicado: (2019)

Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women
por: Mazibuko-Motau, Noluthando, et al.
Publicado: (2022)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities
por: Kim, Susan C, et al.
Publicado: (2010)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention
por: Reidy, Meghan, et al.
Publicado: (2019)

HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review
por: Bradshaw, Daniel, et al.
Publicado: (2022)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Pre-exposure prophylaxis of HIV
por: Naswa, Smriti, et al.
Publicado: (2011)

Pre-exposure prophylaxis in HIV
por: Khambhati, Ravi, et al.
Publicado: (2009)

HIV: Pre-exposure Prophylaxis
por: Singh, Ajai Kumar, et al.
Publicado: (2012)

Women’s Experiences with Oral and Vaginal Pre-Exposure Prophylaxis: The VOICE-C Qualitative Study in Johannesburg, South Africa
por: van der Straten, Ariane, et al.
Publicado: (2014)

Impact of vaginal microbiome communities on HIV antiretroviral-based pre-exposure prophylaxis (PrEP) drug metabolism
por: Cheu, Ryan K., et al.
Publicado: (2020)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses
por: Tsibris, Athe M. N., et al.
Publicado: (2011)

Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium
por: Vanbaelen, Thibaut, et al.
Publicado: (2022)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

HIV pre-exposure prophylaxis for women
por: Sheth, Anandi N, et al.
Publicado: (2016)

Pre-exposure Prophylaxis: The Delivery Challenge
por: Venter, Willem D. F.
Publicado: (2018)

Modeling HIV Pre-Exposure Prophylaxis
por: Straubinger, Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6rtv30lr15jsl0756oal01o9fe